On this page
GLP-1 coverage by insurance: when plans actually pay
n
GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound have gone from diabetes drugs to cultural phenomena in a few short years. Demand is enormous, the monthly price without insurance is painful, and coverage is a mess. Some plans pay with a reasonable copay. Some require months of prior authorization. Some exclude weight-loss use entirely. Whether your plan pays comes down to three things: your diagnosis, your plan’s formulary, and how persistent you are.
n
Why coverage depends on the diagnosis
n
The same drug can be covered or excluded depending on why it was prescribed. GLP-1s approved for type 2 diabetes, like Ozempic and Mounjaro, are usually covered under the pharmacy benefit when prescribed for diabetes, because diabetes treatment is standard medical care that every plan covers. The versions approved for weight management, like Wegovy and Zepbound, face much tougher coverage. Many plans explicitly exclude weight-loss medications as a category, a policy written long before these drugs existed and long before the evidence for their health benefits accumulated.
n
This creates the odd situation where a patient with diabetes gets the drug for a copay while a patient with obesity and prediabetes pays full price, even though both have serious medical conditions. Some plans have started covering the weight-management versions, particularly large employer plans that have run the numbers on long-term health costs. But coverage for weight loss remains the exception, not the rule.
n
Prior authorization is the real gatekeeper
n
Even when your plan covers GLP-1s, you will almost certainly face prior authorization. The plan wants documentation: the diagnosis, previous treatments tried, and often specific clinical criteria like an A1C level for diabetes or a BMI threshold with a related condition for weight management. Some plans require step therapy, meaning you must try and fail on metformin or another older drug first.
n
Prior authorizations for GLP-1s are denied at high rates on the first attempt. This is not necessarily the end. Appeals work, especially with a letter of medical necessity from your doctor documenting why this specific drug is appropriate. If your doctor’s office has a dedicated prior authorization staff member, use them. They do this all day and know what each insurer’s form wants to see. Our guide to prescription drug tiers and formularies explains how plans decide where a drug sits and what that means for your cost.
n
What it costs when insurance says no
n
Without coverage, GLP-1s are among the most expensive common prescriptions in the country, running to four figures per month at list price. Discount coupons barely move the needle on drugs this expensive, a small percentage off a huge number is still a huge number. Our piece on getting GLP-1s without insurance covers the full landscape of options, including manufacturer savings programs, which can meaningfully reduce the cost for commercially insured patients whose plans cover the drug but with a high copay.
n
One strategy people overlook is checking whether their plan covers the drug under a different diagnosis they legitimately have. This is not gaming the system. If you have type 2 diabetes and your doctor prescribes Ozempic for diabetes, that is the labeled use, and it should be covered as diabetes treatment. The prescription needs to match the real diagnosis, but many patients do not realize their existing conditions already qualify them.
n
The coverage landscape is shifting
n
GLP-1 coverage is one of the fastest-moving areas in health insurance. Employers are adding and dropping coverage as they see the actual claims costs. Medicare currently does not cover weight-loss drugs under Part D by statute, though it covers the diabetes versions. State Medicaid programs vary. Because the rules change at every plan renewal, what your plan covers this year may not be what it covers next year. Check the formulary during every open enrollment, and if GLP-1 coverage matters to you, treat it as a first-order factor in choosing a plan, not an afterthought. The difference between covered and not covered is the difference between a copay and a second rent payment.
n
What to do at open enrollment
n
If GLP-1 coverage matters to you, open enrollment is the one moment each year when you can act on it. Pull the formulary for each plan you are considering and search for the specific drug names, not just the drug class. Formularies list drugs individually, and a plan can cover Ozempic while excluding Wegovy, or cover Mounjaro while requiring step therapy. Note the tier placement too, because a covered drug on a specialty tier can still carry a large copay or coinsurance.
n
Also look at the plan’s prior authorization criteria if they are published. Some plans post their clinical criteria online, and reading them tells you whether you are likely to be approved before you enroll. If the criteria require a BMI threshold you do not meet or a diabetes diagnosis you do not have, that plan will not cover the drug for you no matter what the formulary says. Choosing a plan around a specific medication is one of the few times the cheapest premium is the wrong answer. The plan that covers your drug is cheaper than the plan with the low premium that does not.
n
The other trend to watch is employers adding GLP-1 coverage mid-year as they see competitor plans doing it. If your plan excludes weight-loss drugs now, that is not necessarily permanent. Benefits teams revisit these decisions, especially when employees ask. It costs nothing to tell your HR department that coverage matters to you. One employee asking changes nothing, but benefits managers do track what employees request, and GLP-1 coverage is currently one of the most requested additions in employer benefits surveys.
n
